3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
23
Neoplasms
14
Neoplasm Metastasis
14
Glioblastoma
14
Prostatic Neoplasms
13
Breast Neoplasms
11
Brain Neoplasms
11
Sarcoma
10
Lymphoma, Non-Hodgkin
10
Kidney Neoplasms
10
Endometrial Neoplasms
10
Melanoma
9
Lymphoma, Mantle-Cell
9
Gliosarcoma
8
Multiple Myeloma
7
Glioma
7
Ovarian Neoplasms
6
Carcinoma, Hepatocellular
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Oligodendroglioma
5
Lymphoma, Follicular
5
Lymphoma
5
Hodgkin Disease
5
Central Nervous System Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Astrocytoma
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
4
Rhabdomyosarcoma
4
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts